

TM

NEXT GENERATION DRUGS TO TREAT
AUTOIMMUNE, CHRONIC INFLAMMATORY DISEASE
AND CANCER
ABOUT SFA THERAPEUTICS
Our journey began with a deep fascination for the intricate world of the human gut bacterial ecosystem and its profound impact on overall well-being. Our founders, a team of passionate researchers and healthcare professionals, were intrigued by the pivotal role this complex microbiota plays in maintaining human health. The various bacteria produce a complex, yet synergistic, set of metabolites in our intestines that exhibit profound, wide-ranging effects on metabolism and immune function.
​​
​​
​​
​As we delved deeper into the science, we uncovered the potential of these biosynthetic molecules, that mimic naturally occurring substances, in addressing a variety of health challenges, from autoimmune disease to metabolic disorders. We were particularly captivated by how these simple organic compounds could influence complex cellular processes and serve as a communication bridge between our gut microbiome and immune system.
​
​​
​​​​​
We discovered ways of increasing the selectivity and specifictiy of our biosynthetics after elucidating pathways and targets. We have developed a platform technology that allows us to target specific diseases and create disease-specific drugs. ​​​​Our technology platform represents a convergence of microbial science, pharmaceutical innovation, and precision medicine, offering new hope for patients across multiple therapeutic areas.
​
​Join us on this exciting journey as we work towards a healthier future, one molecule at a time.



INNOVATIVE DRUGS
PREDICTABLE OUTCOMES
Innovative Oral Formulations Allow for Consistent Clinical Outcomes
PATHWAY TARGETED
Small Molecules that Interact Selectively with Disease-specific Targets and Maintain Immune Homeostasis
SUPERIOR
SAFETY
Small Molecules that Mimic Endogenous Substances found in the Human Body
HIGHLY EFFICACIOUS
Boosts Anti-inlammatory IL-10 Expression and Downregulates Pro-inflammatory Cytokines
LOW COST
Seamless Manufacturing Process
POWERFUL and NOVEL PLATFORM
![102158395_eps_normal_none [Converted].png](https://static.wixstatic.com/media/abea01_08ad758a19dd4b5f976a8010220e7a2d~mv2.png/v1/fill/w_119,h_143,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/102158395_eps_normal_none%20%5BConverted%5D.png)
1
2
3
4



TARGETED BIOSYNTHESIS
PLATFORM

5

AUTOIMMUNE DISEASES
PSORIASIS, RHEUMATOID ARTHRITIS,
UVEITIS AND BULLOUS PEMPHIGOID
CANCERS
HEPATOCELLULAR CARCINOMA, PANCREATIC CANCER AND MYELOID LEUKEMIAS
INFECTIOUS DISEASES
POST-VIRAL INFLAMMATORY COMPLICATIONS​
LIVER DISEASES
FIBROSIS AND MASH/NASH ​
ANTI-INFLAMMATORY ADJUVANTS
CAR-T THERAPIES
OUR PARTNERS
SFA THERAPEUTICS
IS A
VENTURE CAPITAL BACKED CLINICAL-STAGE BIOTECHNOLOGY COMPANY









SFA THERAPEUTICS IN THE NEWS

JENKINTOWN, Pa., March 13, 2025 BioWorld -- First-in-class oral immunomodulator shows efficacy in psoriasis models​
JENKINETOWN, PA., March 13, 2025 --Technical.ly This pharma startup backed by Y Combinator aims to treat multiple diseases, for good
JENKINTOWN, Pa., March 7, 2025 BUSINESS WIRE -- SFA Therapeutics Announces Positive Phase 1b Data of SFA-002 in Mild-to-Moderate Psoriasis
JENKINTOWN, Pa., March 7, 2025 PR NEWSWIRE -- Head-to-Head Preclinical Studies of SFA-002 as a Novel Psoriasis Treatment Presented at the 2025 American Academy of Dermatology Annual Meeting
JENKINTOWN, Pa., January 15, 2025 Scrip -- Scrip Asks… What Does 2025 Hold For Biopharma? Part 2: Funding, M&A And Partnering - Early Stage Deals
JENKINTOWN, Pa., January 5, 2025-- Philadelphia Inquirer New Scientific Discoveries Yield Impressive Real-World Applications